Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego
15 Agosto 2023 - 5:15PM
Business Wire
Awards mark Veracyte’s 10th consecutive honor
in the Bay Area and inaugural recognition in San Diego
Veracyte, Inc. (Nasdaq: VCYT) announced that its South San
Francisco and San Diego offices have been named top workplaces.
Veracyte’s South San Francisco location has been awarded a Top Bay
Area Workplaces 2023 honor by the San Francisco Chronicle, in
partnership with Energage, LLC. This is Veracyte’s tenth
consecutive year receiving this honor. Additionally, Veracyte’s San
Diego office has received its inaugural Best Places to Work in San
Diego award by the San Diego Business Journal (SDBJ), in
partnership with Workforce Research Group.
The Bay Area award list is based on anonymous employee feedback
gathered by Energage, a third-party survey administrator. The
evaluation measured 15 culture drivers that are critical to
organization success including alignment, execution and connection.
For the San Diego award, the SDBJ and Workforce Research Group
conducted a detailed analysis of company workplace policies and
practices along with a comprehensive, anonymous employee survey.
The combined scores determined the top San Diego companies.
“We are honored to be recognized as a top workplace in both the
San Francisco Bay Area and San Diego,” said Marc Stapley,
Veracyte’s chief executive officer. “These awards reflect the hard
work and dedication of our employees, who are committed to our
vision of transforming cancer care for patients all over the world.
We are proud to create a workplace where employees feel valued,
supported and empowered to make a difference in patients’
lives.”
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose
vision is to transform cancer care for patients all over the world.
We empower clinicians with the high-value insights they need to
guide and assure patients at pivotal moments in the race to
diagnose and treat cancer. Our high-performing tests enable
clinicians to make more confident diagnostic, prognostic, and
treatment decisions for some of the most challenging diseases such
as thyroid, prostate, breast, bladder and lung cancers, as well as
interstitial lung diseases. We help patients avoid unnecessary
procedures and speed time to diagnosis and appropriate treatment.
In addition to making our tests available in the U.S. through our
central laboratories, we also aim to deliver our tests to patients
worldwide through a distributed model to laboratories that can
perform them locally. Veracyte is based in South San Francisco,
California. For more information, please visit www.veracyte.com and
follow the company on Twitter (@veracyte).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230815554301/en/
Investors: Shayla Gorman Director, Investor Relations
investors@veracyte.com 619-393-1545
Media: Brad Lotterman Director, Corporate Communications
Brad.lotterman@veracyte.com 760-579-3509
Veracyte (NASDAQ:VCYT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Veracyte (NASDAQ:VCYT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024